Merck begins Phase III letermovir trial for prevention of CMV infection

US-based pharmaceutical firm Merck has enrolled the first patient in a global Phase III clinical trial of letermovir (MK-8228), an investigational antiviral agent, for prevention of cytomegalovirus (CMV) infection in high-risk bone marrow transplant …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news